Vaccines are important for protecting individuals at increased risk of severe infections,
including patients undergoing DMARD therapy. However, DMARD therapy can also …

The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In
addition to the general effect on society and health-care systems, patients with systemic …

Objectives To characterize the kinetics of humoral and T-cell responses in rheumatoid
arthritis (RA)-patients followed up to 4-6 weeks (T3) after the SARS-CoV-2 vaccine booster …

Background By depleting circulating B lymphocytes, rituximab time-dependently suppresses
coronavirus disease 2019 (COVID-19) vaccines' humoral immunogenicity for a prolonged …

Objective The level of neutralising capacity against Omicron BA. 1 and BA. 2 after third
COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is …

Objectives A third COVID-19 vaccination is recommended for immunosuppressed patients.
However, data on immunogenicity and safety of a third COVID-19 vaccination in patients …

Background Patients with autoimmune/inflammatory conditions on anti-CD20 therapies,
such as rituximab, have suboptimal humoral responses to vaccination and are vulnerable to …

Background & aims To explore the humoral and T‐cell response to the third COVID‐19
vaccination in autoimmune hepatitis (AIH). Methods Anti‐SARS‐CoV‐2 antibody titers were …

Only case reports and small clinical series report the effects of booster vaccination with
BNT162b2 in patients with rheumatoid arthritis (RA). We studied 200 patients with RA in …

Objectives To evaluate humoral responses to three doses of the inactivated SARS-CoV-2
vaccine (CoronaVac) in patients with spondyloarthritis (SpA) and the effect of therapy …